학술논문
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
Document Type
article
Author
Wenxian Wang; Qian Wang; Chunwei Xu; Ziming Li; Zhengbo Song; Yongchang Zhang; Xiuyu Cai; Shirong Zhang; Bin Lian; Wen Li; Anwen Liu; Ping Zhan; Hongbing Liu; Tangfeng Lv; Liyun Miao; Lingfeng Min; Yu Chen; Jingping Yuan; Feng Wang; Zhansheng Jiang; Gen Lin; Xingxiang Pu; Chuangzhou Rao; Dongqing Lv; Zongyang Yu; Xiaoyan Li; Chuanhao Tang; Chengzhi Zhou; Congying Xie; Junping Zhang; Hui Guo; Qian Chu; Rui Meng; Jingxun Wu; Rui Zhang; Liping Wang; Youcai Zhu; Xiao Hu; Yanru Xie; Xinqing Lin; Jing Cai; Fen Lan; Huijing Feng; Lin Wang; Wang Yao; Xuefei Shi; Jianhui Huang; Huafei Chen; Yinbin Zhang; Pingli Sun; Bing Wan; Fei Pang; Zanmei Xu; Kai Wang; Yuanli Xia; Mingxiang Ye; Dong Wang; Qing Wei; Shuitu Feng; Jianya Zhou; Jiexia Zhang; Donglai Lv; Wenbin Gao; Jing Kang; Genhua Yu; Xianbin Liang; Chengtao Yu; Lin Shi; Nong Yang; Lin Wu; Zhuan Hong; Wei Hong; Meiyu Fang; Yiping Zhang; Yuanzhi Lu; Guansong Wang; Shenglin Ma; Lu Si; Wenfeng Fang; Yong Song
Source
Thoracic Cancer, Vol 13, Iss 23, Pp 3420-3430 (2022)
Subject
Language
English
ISSN
1759-7714
1759-7706
1759-7706
Abstract
Abstract Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in‐depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.